209 related articles for article (PubMed ID: 20800692)
41. In vitro culture of Plasmodium berghei-ANKA maintains infectivity of mouse erythrocytes inducing cerebral malaria.
Jambou R; El-Assaad F; Combes V; Grau GE
Malar J; 2011 Nov; 10():346. PubMed ID: 22118493
[TBL] [Abstract][Full Text] [Related]
42. Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model.
Souraud JB; Briolant S; Dormoi J; Mosnier J; Savini H; Baret E; Amalvict R; Soulard R; Rogier C; Pradines B
Malar J; 2012 Jan; 11():13. PubMed ID: 22233563
[TBL] [Abstract][Full Text] [Related]
43. Effects of anti-tau immunotherapy on reactive microgliosis, cerebral endotheliopathy, and cognitive function in an experimental model of cerebral malaria.
Akide Ndunge OB; Shikani HJ; Dai M; Freeman BD; Desruisseaux MS
J Neurochem; 2023 Nov; 167(3):441-460. PubMed ID: 37814468
[TBL] [Abstract][Full Text] [Related]
44. MDR1A (ABCB1)-deficient CF-1 mutant mice are susceptible to cerebral malaria induced by Plasmodium berghei ANKA.
de Lagerie SB; Fernandez C; German-Fattal M; Gantier JC; Gimenez F; Farinotti R
J Parasitol; 2008 Oct; 94(5):1139-42. PubMed ID: 18973419
[TBL] [Abstract][Full Text] [Related]
45. Plasmodium berghei NK65: studies on the effect of treatment duration and inoculum size on recrudescence.
Nakazawa S
Exp Parasitol; 2005 Sep; 111(1):59-63. PubMed ID: 15961077
[TBL] [Abstract][Full Text] [Related]
46. T-lymphocytes response persists following Plasmodium berghei strain Anka infection resolution and may contribute to later experimental cerebral malaria outcomes.
de Miranda AS; Ferreira RN; Vieira ÉLM; Abreu LKS; Brant F; Vieira LB; Ribeiro FM; Machado FS; Rachid MA; Teixeira AL
J Neuroimmunol; 2019 May; 330():5-11. PubMed ID: 30763800
[TBL] [Abstract][Full Text] [Related]
47. Ethanolic extract of the fungus Trichoderma stromaticum decreases inflammation and ameliorates experimental cerebral malaria in C57BL/6 mice.
Cariaco Y; Lima WR; Sousa R; Nascimento LAC; Briceño MP; Fotoran WL; Wunderlich G; Dos Santos JL; Silva NM
Sci Rep; 2018 Jan; 8(1):1547. PubMed ID: 29367729
[TBL] [Abstract][Full Text] [Related]
48. Complement C5-deficient mice are protected from seizures in experimental cerebral malaria.
Buckingham SC; Ramos TN; Barnum SR
Epilepsia; 2014 Dec; 55(12):e139-42. PubMed ID: 25385326
[TBL] [Abstract][Full Text] [Related]
49. α-Tocopheryl succinate-suppressed development of cerebral malaria in mice.
Kume A; Kasai S; Furuya H; Suzuki H
Parasitol Res; 2018 Oct; 117(10):3177-3182. PubMed ID: 30030625
[TBL] [Abstract][Full Text] [Related]
50. Suppression of Plasmodium berghei parasitemia by LiCl in an animal infection model.
Nurul Aiezzah Z; Noor E; Hasidah MS
Trop Biomed; 2010 Dec; 27(3):624-31. PubMed ID: 21399604
[TBL] [Abstract][Full Text] [Related]
51. Endothelin-1 Treatment Induces an Experimental Cerebral Malaria-Like Syndrome in C57BL/6 Mice Infected with Plasmodium berghei NK65.
Martins YC; Freeman BD; Akide Ndunge OB; Weiss LM; Tanowitz HB; Desruisseaux MS
Am J Pathol; 2016 Nov; 186(11):2957-2969. PubMed ID: 27640146
[TBL] [Abstract][Full Text] [Related]
52. Antimalarial properties of Goniothalamin in combination with chloroquine against Plasmodium yoelii and Plasmodium berghei growth in mice.
Mohd Ridzuan MA; Ruenruetai U; Noor Rain A; Khozirah S; Zakiah I
Trop Biomed; 2006 Dec; 23(2):140-6. PubMed ID: 17322815
[TBL] [Abstract][Full Text] [Related]
53. Neuroimmunological blood brain barrier opening in experimental cerebral malaria.
Nacer A; Movila A; Baer K; Mikolajczak SA; Kappe SH; Frevert U
PLoS Pathog; 2012; 8(10):e1002982. PubMed ID: 23133375
[TBL] [Abstract][Full Text] [Related]
54. Endothelin-1 Mediates Brain Microvascular Dysfunction Leading to Long-Term Cognitive Impairment in a Model of Experimental Cerebral Malaria.
Freeman BD; Martins YC; Akide-Ndunge OB; Bruno FP; Wang H; Tanowitz HB; Spray DC; Desruisseaux MS
PLoS Pathog; 2016 Mar; 12(3):e1005477. PubMed ID: 27031954
[TBL] [Abstract][Full Text] [Related]
55. Improved efficacy of doxycycline in liposomes against Plasmodium falciparum in culture and Plasmodium berghei infection in mice.
Rajendran V; Singh C; Ghosh PC
Can J Physiol Pharmacol; 2018 Nov; 96(11):1145-1152. PubMed ID: 30075085
[TBL] [Abstract][Full Text] [Related]
56. Controlled release of artemisone for the treatment of experimental cerebral malaria.
Golenser J; Buchholz V; Bagheri A; Nasereddin A; Dzikowski R; Guo J; Hunt NH; Eyal S; Vakruk N; Greiner A
Parasit Vectors; 2017 Mar; 10(1):117. PubMed ID: 28249591
[TBL] [Abstract][Full Text] [Related]
57. Magnetic resonance spectroscopy reveals an impaired brain metabolic profile in mice resistant to cerebral malaria infected with Plasmodium berghei ANKA.
Penet MF; Kober F; Confort-Gouny S; Le Fur Y; Dalmasso C; Coltel N; Liprandi A; Gulian JM; Grau GE; Cozzone PJ; Viola A
J Biol Chem; 2007 May; 282(19):14505-14. PubMed ID: 17369263
[TBL] [Abstract][Full Text] [Related]
58. Cysteamine broadly improves the anti-plasmodial activity of artemisinins against murine blood stage and cerebral malaria.
Moradin N; Torre S; Gauthier S; Tam M; Hawari J; Vandercruyssen K; De Spiegeleer B; Fortin A; Stevenson MM; Gros P
Malar J; 2016 May; 15(1):260. PubMed ID: 27150250
[TBL] [Abstract][Full Text] [Related]
59. CD4+ CD25+ regulatory T cells suppress CD4+ T-cell function and inhibit the development of Plasmodium berghei-specific TH1 responses involved in cerebral malaria pathogenesis.
Nie CQ; Bernard NJ; Schofield L; Hansen DS
Infect Immun; 2007 May; 75(5):2275-82. PubMed ID: 17325053
[TBL] [Abstract][Full Text] [Related]
60. Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model.
Dormoi J; Briolant S; Desgrouas C; Pradines B
Malar J; 2013 Apr; 12():127. PubMed ID: 23587099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
